Making Covid-19 vaccine available for children will be a milestone achievement and pave the way for reopening of schools and resumption of outdoor activities for them, AIIMS Chief Dr Randeep Guleria has said. He said the data of phase two and three trial of Bharat Biotech's Covaxin on two to 18 years age group is expected by September. The vaccine can be available for children in India around that time following approval from the drug regulator, he said.

Making Covid-19 vaccine available for children will be a milestone achievement and pave the way for reopening of schools and resumption of outdoor activities for them, AIIMS Chief Dr Randeep Guleria has said. He said the data of phase two and three trial of Bharat Biotech's Covaxin on two to 18 years age group is expected by September. The vaccine can be available for children in India around that time following approval from the drug regulator, he said.